Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | THPO | P40225 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | THRB | P10828 | 3/20 | 0.64 |
| ▸ | BLM | P54132 | 3/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343231 | 0.97 | CYP2D6 (0.71) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| Iodomethane SCHEMBL2339134 | 0.94 | CYP2D6 (0.67) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| SCHEMBL17294730 | 0.84 | CYP2D6 (0.68) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| SCHEMBL17294776 | 0.84 | CYP2D6 (0.68) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| SCHEMBL17294736 | 0.84 | CYP2D6 (0.68) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| SCHEMBL16789090 | 0.83 | MEN1 (0.57) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| SCHEMBL7649270 | 0.82 | CYP2D6 (0.77) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| Hydrochloric Acid SCHEMBL28125818 | 0.82 | MEN1 (0.59) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| SCHEMBL24671171 | 0.81 | CYP2D6 (1.00) | CYP2D6HTTCYP1A2CYP3A4TP53 | |
| SCHEMBL10517998 | 0.81 | CYP2D6 (0.60) | CYP2D6HTTCYP1A2CYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4385521-A2 | STORAGE STABLE COMPOSITIONS AND METHODS FOR THE TREATMENT OF REFRACTIVE ERRORS OF THE EYE | Lenz Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240091207-A1 | COMPOSITIONS AND METHODS FOR STORAGE STABLE OPHTHALMIC DRUGS | LENZ THERAPEUTICS OPERATIONS, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2023114347-A9 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE CONDITIONS | LENZ THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20230414587-A1 | COMPOSITIONS AND METHODS FOR STORAGE STABLE OPHTHALMIC DRUGS | LENZ THERAPEUTICS OPERATIONS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230414494-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230404912-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS, INC. | 2023-12-21 | — | — | US | disclosed |
| US-20230398064-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398113-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230310392-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE CONDITIONS | LENZ THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-116847841-A | Composition and storage method for stabilizing ophthalmic drug | 伦茨治疗股份有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20150290126-A1 | Compositions and Methods for the Improvement of Distance Vision and the Treatment of Refractive Errors of the Eye | LENZ THERAPEUTICS OPERATIONS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150290125-A1 | Storage Stable Compositions and Methods for the Treatment of Refractive Errors of the Eye | LENZ THERAPEUTICS OPERATIONS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-9089562-B2 | Compositions and methods for the treatment of presbyopia | PRESBYOPIA THERAPIES LLC (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150065511-A1 | Compositions and Methods for the Treatment of Presbyopia | Presbyopia Therapies, LLC (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2015031186-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | PRESBYOPIA THERAPLIES, LLC (US) | 2015-03-05 | — | — | WO | disclosed |
| EP-0382687-B1 | Benzofused-N-containing heterocycle derivatives | BOEHRINGER INGELHEIM ITALIA (IT) | 1995-12-27 | — | — | EP | disclosed |
| US-5446057-A | Antiulcer agent, antisecretory agent, drug treating urogenital disorder, parkinson*s disease and alzheimer*s disease | WARNER-LAMBERT COMPANY (US) | 1995-08-29 | — | — | US | disclosed |
| US-5164386-A | Gastrointestinal and respiratory disorders | ISTITUTO DE ANGELI S.P.A. (IT) | 1992-11-17 | — | — | US | disclosed |
| US-5106851-A | Respiratory system disorders | ISTITUTO DE ANGELI S.P.A. (IT) | 1992-04-21 | — | — | US | disclosed |
| EP-0382687-A2 | Benzofused-N-containing heterocycle derivatives | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065511-A1 | Compositions and Methods for the Treatment of Presbyopia | ADRB2, AGTR2, ADRA2C | CYP2D6 3749/4885HTT 3609/4885CYP1A2 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.